Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
复制标题
DOI：
10.1158/1078-0432.ccr-07-4122
复制
发表时间：
2008-03-15
影响因子：
11.5
通讯作者：
Filipits, Martin
中科院分区：
文献类型：
--
作者：
Rudas, Margaretha;Lehnert, Martina;Filipits, Martin
目的：我们的研究的目的是确定激素受体阳性的乳腺癌患者中细胞周期蛋白D1的表达与他莫昔芬为基础的therapeutic.Experimental Designs治疗的临床相关性：我们评估细胞周期蛋白D1的表达在乳腺癌手术标本的免疫组化方法。患者已入选奥地利乳腺癌和结直肠癌研究组（ABCSG）试验05或ABCSG试验06，并接受他莫昔芬作为辅助治疗的一部分。总生存率和无复发生存率进行了分析与考克斯模型调整临床和病理factors.Results：细胞周期蛋白D1表达在140 253（55%）肿瘤的ABCSG试验05和569 948（60%）肿瘤的ABCSG试验06。在两个队列中，细胞周期蛋白D1的表达与不良结局相关。与cyclin D1阴性肿瘤患者相比，cyclin D1阳性肿瘤患者的总生存期显著缩短[死亡的校正风险比（HR（ABCSG试验05），2.47; 95%置信区间（95% CI），1.08-5.63; P = 0.03;死亡校正HR（ABCSG试验06），1.78; 95% CI，1.36-2.34; P < 0.0001]。细胞周期蛋白D1阳性肿瘤患者的无复发生存期也比细胞周期蛋白D1阴性肿瘤患者短[根据复发调整HR（ABCSG试验05），2.73; 95% CI，1.50-4.96; P = 0.001;复发校正HR（ABCSG Trial 06），1.52; 95%CI，1.14-2.04; P = 0.0051。结论：Cyclin D1表达是激素受体阳性的早期乳腺癌患者接受三苯氧胺辅助治疗的独立不良预后因素。
Purpose: The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifenbased therapy.Experimental Design: We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochemistry. Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment. Overall survival and relapse-free survival were analyzed with Cox models adjusted for clinical and pathologic factors.Results: Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06. Expression of cyclin D1 was associated with poor outcome in both cohorts. Overall survival was significantly shorter in patients with cyclin D1 - positive tumors compared with patients with cyclin D1 - negative tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% Cl), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06),1.78; 95% Cl, 1.36-2.34; P < 0.0001]. Relapse-free survival was also shorter in patients with cyclin D1 - positive tumors than in patients with cyclin D1 - negative tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% Cl, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06),1.52; 95% Cl, 1.14-2.04; P = 0.0051.Conclusion: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy.